TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the current Diagnostic and Statistical Manual with Mental Disorders (DSM-IV-TR) for Autism (Autistic Disorder), screened by SCQ and confirmed by ADI-R;~Exclusion Criteria:~* Patient weighing \< 13kg (28.6 lbs)~* Previous allergy to porcine (pork) products~* Previous history of severe head trauma or stroke, loss of consciousness, seizure (or need for seizure medication either present or past) within one year of entering study or uncontrolled systemic disease~* Diagnosis of: HIV, cerebral palsy, endocrine disorder, pancreatic disease, muscular dystrophy, known genetic disorder, blood dyscrasia, ongoing GI disease~* Evidence of severe, moderate or uncontrolled systemic disease; and/or any co-morbid condition which in the Investigator's or Medical Director's opinion makes it undesirable for the subject to participate in the study or jeopardizes compliance with the protocol;~* Within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion);~* Ongoing dietary restriction for allergy or other reasons except nut allergies (lactose-free allowable);~* Use of of any stimulant medication must be discontinued 5 days prior to entering the study.~* Subject must have a stable dose of SSRI's for at least 30 days.~* Inability to ingest study drug and/or follow prescribed dosing schedule

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- CM-AT (Type: EXPERIMENTAL): Active substance in single unit dose powder
- Placebo (Type: PLACEBO_COMPARATOR): Placebo powder of inactive substance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive Impact of Paracetamol in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers,~* aged over 18 years and not more than 25 years,~* males,~* free from any treatment in the 7 days preceding inclusion especially no use of analgesics or anti-inflammatories~Exclusion Criteria:~* Contraindications to the administration of paracetamol~* medical and/or surgical history judged by the investigator or his representative as being incompatible with the test, especially subjects with neuropathic pain~* evolutionary pathology at review for inclusion~* excessive intake of alcohol, tobacco (more than 10 cigarettes / day), coffee, tea or drinks containing caffeine (equivalent to more than 4 cups per day) or drug

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of a Syringe Pump to Pre-eclamptic Women in a Low-resource Hospital

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Phase 1: Healthy Volunteers~Inclusion Criteria:~* 18 years of age or older~* Provide informed consent~* Agree to comply with study procedures~* Deemed medically stable by their healthcare provider, including normal range blood pressure.~* Have been clinically identified to be able to receive standard IV saline fluid~Exclusion Criteria:~* Women with a history of heart disease of cardiac complications.~* Women with a history of complications with an IV.~Phase 2: Pre-eclamptic Women~Inclusion Criteria:~* 18 years of age or older~* Provide informed consent~* Agree to comply with study procedures~* Have systolic blood pressure P140mm Hg or a diastolic blood pressure P100mm Hg and proteinuria P1+.~* Be pregnant or are \<24 hours postpartum.~* Diagnosed with pre-eclampsia and deemed to benefit from treatment with MGSO4 by healthcare providers~Exclusion Criteria:~* Have systolic blood pressure P140mm Hg or a diastolic blood pressure P100mm Hg and proteinuria P1+.~* Be pregnant or are \<24 hours postpartum.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Adults (Type: ACTIVE_COMPARATOR): Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
- Pre-eclamptic pregnant women (Type: EXPERIMENTAL): In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 and previously diagnosed with at least 1 of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease~* History of at least one unsuccessful dietary effort to lose body weight~Exclusion Criteria:~* Diabetes mellitus~* Change in body weight greater than 5 kg within 3 months prior to starting study~* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity~* History of pancreatitis~* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)~* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years~* Any lifetime history of a suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tirzepatide (Type: EXPERIMENTAL): Participants received weekly doses of tirzepatide subcutaneously (SC) for 72 weeks, starting at 2.5 milligrams (mg) for 4 weeks. Subsequently, the dose was increased by 2.5 mg every 4 weeks up to the maximum tolerated dose (MTD) of either 10 mg or 15 mg.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo SC once weekly (QW).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male, non-smoker, 21-75 years of age~* female, non-smoker, 40-75 years of age~* post-menopausal women, as defined by lack of menses for at least 2 years and age \>55, OR history of documented bilateral oophorectomy, confirmed with an elevated FSH at screening~* low-density lipoprotein (LDL) concentration between 130-200 mg/dL.~* triglyceride (TG) concentration \<350 mg/dL, inclusive~* high-density lipoprotein (HDL) between 30-60 mg/dL for men and 40 -70 mg/dL for women~* ability to give informed consent~Exclusion Criteria:~* Subject has history of diabetes mellitus, active hepatitis, gall bladder disease, gastric or ileal bypass surgery, irritable bowel syndrome, and gastrointestinal disorder/condition associated with malabsorption, or clinically significant abnormalities on screening (prestudy) physical examination of laboratory tests.~* Screening laboratory tests with hematocrit \<30%, aspartate aminotransferase/alanine aminotransferase (AST/ALT) \>2\*upper limit of normal, abnormal thyroid-stimulating hormone (TSH), fasting glucose \>=126mg/dL~* renal impairment with creatinine clearance (CRCl)\<80ml/min~* treatment within the last 2 months with drugs known to alter lipid metabolism including beta blockers, thiazide diuretics, bile acid resins, statins, ezetimibe, niacin, fibrates, plant stanol esters (eg Benecol,phyto sterols) and fishoils~* history of known coronary heart disease (CHD), stroke or prior revascularization procedure or peripheral vascular disease~* history of allergy to egg or soy products~* current or recent (past 12 months) of drug abuse or alcohol abuse. Alcohol use must be limited to no more than 2 drinks/day (1 drink=12 oz beer, 5 oz wine, or 1.5 oz hard liquor). Subject must be willing to avoid large day-to-day fluctuations in alcohol intake.~* participation in another clinical trial or exposure to any investigational agent within 30 days prior to Visit 1~* Individual has a condition the Principal Investigator believes would interfere with his/her ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results, or put the subject at undue risk

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): ezetimibe (10mg/day)for 7 weeks
- 2 (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male patients aged 6 to 15 years.~* Patients with autism spectrum disorder diagnosed by using DSM-5.~* Patients with average of daily sleep latency persisted over 30 min and the condition is continuous over 3 months~* Patients who are out-patient, not hospitalized patient.~* Signed informed consent obtained from rearer(s)/parent(s)/guardian(s) of the patient, or signed IC or informed assent obtained from the patient themselves.~Exclusion Criteria:~* Patients with at least severity in either Conceptual area, or Social area, or Practical area of intellectual disability have judged more than severe by using DSM-5.~* Patients who took melatonin (including supplement) in history.~* Patients who had taken Ramelteon within 4 weeks before clinical study starts.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- NPC-15 Granules Lower Dose (Type: EXPERIMENTAL): NPC-15 Granules Lower Dose group which is administered 1mg melatonin
- NPC-15 Granules Higher Dose (Type: EXPERIMENTAL): NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
- NPC-15 Placebo Granule (Type: PLACEBO_COMPARATOR): NPC-15 Placebo Granules group which is administered placebo melatonin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Male or non-pregnant female aged 40-75 with chronic moderate to severe knee pain due to OA (scoring 50 out of 100 on a visual analog scale on knee pain).~Subjects must meet one of the following: unwilling to take non-opiate pain medications, or for whom non-opiate pain medications have failed, or are candidates for or seeking invasive interventions such as intraarticular injections, knee arthroplasty, or total knee surgery~Exclusion Criteria:~History or symptoms of autoimmune disorders, cancer within the last 5 years except for cutaneous basal cell or squamous cell cancer resolved by excision, allergic reaction to monoclonal antibodies or IgG-fusion proteins, Hepatitis B, C or HIV, drug abuse, fibromyalgia, clinically significant cardiac disease, diabetes mellitus requiring oral treatment or insulin, clinically significant neurological disease or clinically significant psychiatric disorders

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): monoclonal antibody
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipids of the Human Tear Film and Their Effect on Tear Stability

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meibomian gland dysfunction~Exclusion Criteria:~* Lid margin scarring; herpetic blepharitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Doxycycline (Type: ACTIVE_COMPARATOR): Oral doxycycline
- azithromycin (Type: ACTIVE_COMPARATOR): Topical azithromycin daily to the conjunctival culdesac

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with active Crohn's disease and a Crohn's disease activity index score between 220 and 450 points~Exclusion Criteria:~* Patient who has previously received a biological agent for the treatment of Crohn's disease and/or a Tumor necrosis factor (TNF)-alpha inhibitor for the treatment of other disease.~* Patient who has allergies to any of the excipients of infliximab, any other murine and/or human proteins, or patient with a hypersensitivity to immunoglobulin product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 - CT-P13 (Type: EXPERIMENTAL): CT-P13 followed by CT-P13 from Week 30
- CT-P13 - Remicade (Type: ACTIVE_COMPARATOR): CT-P13 followed by Remicade from Week 30
- Remicade - Remicade (Type: ACTIVE_COMPARATOR): Remicade followed by Remicade from Week 30
- Remicade - CT-P13 (Type: EXPERIMENTAL): Remicade followed by CT-P13 from Week 30

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 60 years;~* DSM-5 (Diagnostic and statistical manual-5) diagnosis of major depressive disorder, single or recurrent episode;~* Subjective cognitive decline, defined as endorsing 20% of items on the Cognitive Complaint Index (CCI);~* depression severity: MADRS (Montgomery-Asberg Depression Rating Scale) ≥ 15;~* cognition: MOCA (Montreal Cognitive Assessment) ≥ 24;~* fluent in English;~* intact hearing / vision allowing completion of study procedures;~* for individuals on antidepressants at study entry, they must be on a stable dose for at least 6 weeks.~Exclusion Criteria:~* Other Axis I psychiatric disorders, except for anxiety symptoms occurring in a depressive episode;~* History of alcohol or drug dependence or abuse in the last 3 years;~* Tobacco or nicotine use in last year;~* History of a developmental disorder or IQ score \< 70;~* Acute suicidality;~* Acute grief (\<1 month);~* Current or past psychosis;~* Primary neurological disorder, including dementia, stroke, brain tumors, etc.;~* Any MRI contraindication;~* Unstable medical illness;~* Allergy or hypersensitivity to nicotine patches;~* Regular use of drugs with centrally acting cholinergic or anticholinergic properties in last 4 weeks, including acetylcholinesterase inhibitors;~* Current or planned psychotherapy;~* Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in last two months.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transdermal nicotine patch (Type: EXPERIMENTAL): Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* relapsing remitting and secondary progressive MS patients~* between the ages of 18 and 60~* report cognitive difficulties.~* perform 1 sd or more below cut-off on cognitive screening measure~Exclusion Criteria:~* no history of alcohol/drug abuse or nervous system disorder other than MS~* no sensory impairments that might interfere significantly with cognitive testing~* no developmental history of learning disability or attention-deficit/hyperactivity disorder~* no medical condition other than MS that could substantially affect cognition~* no relapse and/or corticosteroid use within four weeks of assessment;~* no current use of modafinil, armodafinil or other psychostimulants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- armodafinil and placebo (Type: EXPERIMENTAL): All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who received dexmedetomidine during their Emergency stay~* Patients who received diazepam during their Emergency stay~* CIE-10 codes consistent with alcohol withdrawal during hospitalization~* CIWA-A score \>10 points~Exclusion Criteria:~* comorbid disease, including several with CNS trauma or cerebrovascular accidents, one with end-stage metastatic carcinoma, and one patient with severe sepsis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: SHAM_COMPARATOR): Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.~Dosage form: DEX 0.2-0.7 mcg/Kg/min.
- Diazepam (Type: ACTIVE_COMPARATOR): Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete